Sign Out
Tafluprost: Moderate to severe photophobia and ocular inflammation such as iritis were frequently seen in a clinical trial with concomitant administration of tafluprost and omidenepag isopropyl at dose of 0.003% to 0.03%. Although concomitant use of Eybelis with tafluprost has not been studied, concomitant use may increase the risk of ocular inflammation because tafluprost is known to be associated with ocular inflammation. Therefore, Eybelis must not be used concomitantly with tafluprost (see 'Contraindications').
Glaucoma/ocular hypertension medications (such as timolol maleate) excluding tafluprost: Frequency of ocular inflammatory adverse reactions including conjunctival hyperemia was elevated in a clinical trial with concomitant administration of Eybelis and timolol maleate. There is no experience of concomitant use with other drugs. Therefore, concomitant use of Eybelis with other glaucoma/ocular hypertension medications should be done with caution.
